Sector News

Latest Allergan buzz puts Ireland’s Jazz in its dealmaking sights

September 8, 2014
Life sciences

Get involved in the discussion! Click here to comment on this story

Forget Salix Pharmaceuticals and long-gone Shire. No. 1 on Allergan’s list of defensive acquisition prospects could be Ireland’s Jazz Pharmaceuticals.
The Dublin drugmaker is the most viable option for Allergan, which hopes a pickup of its own will thwart a hostile takeover attempt from Valeant, three industry bankers told dealReporter (as cited by Benziga).
Jazz, with its tax-advantaged Irish address, could be the lifeline Allergan’s been looking for. Analysts have long said bulking up could help the Botox-maker fend Valeant off, and a lowered tax rate would negate one of the proposed benefits of a merger with the Canadian drugmaker.
That’s not to mention Jazz’s own merits, which include some of the best profit margins in the drug industry. The tiny company has been beefing itself up lately, too; in December it paid $1 billion to buy Italy-based Gentium in a deal analysts said could make Jazz a more attractive target.
But plenty of rumors have been flying since CEO J. Michael Pearson’s deal machine made its first bid for Allergan this spring. First in the spotlight was Ireland’s Shire, which AbbVie quickly moved in to snap up in July. More recently, a potential move for North Carolina’s Salix had industry-watchers abuzz.
And to say Jazz is a rumor-mill regular would be an understatement. The specialty pharma, which makes the narcolepsy treatment Xyrem, has long made the list of pharma’s perennial takeover targets, though so far, it’s survived pharma’s tax inversion frenzy.
Still, speculation fueled a 7% rise in Jazz’ stock price Friday, and thanks to Ireland’s buyout rules, it may not be long before we know if the two parties really are engaged in M&A talks.
As Sterne Agee analyst Shibani Malhotra wrote in a note to clients, the Irish Takeover Panel’s rules require that an announcement regarding the offer be made in the event of an “anomalous movement in share price.”
“In our view there should be further clarity in the next few business days with either a disclosure confirming takeover talks or a lack of an announcement following what appears to be an Irish Takeover Panel disclosure triggering event,” he wrote.
By Carly Helfand

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

November 18, 2019

Bristol-Myers’ $74B Celgene buy wins antitrust nod in FTC party-line split vote

Life sciences

LinkedIn Twitter FacebookIndustry watchers largely expected that Bristol-Myers Squibb and Celgene would win U.S. antitrust clearance for their $74 billion merger. But what’s perhaps unexpected is that the permission was […]

November 18, 2019

Novartis pivots Shanghai R&D site from early discovery to development

Life sciences

LinkedIn Twitter FacebookNovartis is calling it curtains on early drug discovery at its R&D site in Shanghai in a companywide move to “rebalance” its discovery and early development efforts. The […]

November 15, 2019

Merck builds in CNS diseases with $576m Calporta buy

Life sciences

LinkedIn Twitter FacebookMerck & Co has had mixed fortunes in neurological diseases of late, but remains committed to the category and has just bolstered its early-stage pipeline with a $576 […]

Subscribe to our Weekly Newsletter

We're easy to reach